solute carrier family 17 member 5Genealiases: AST · ISSD · NSD · SD · SIALIN · SIASD
Q-omics provides the consensus-scored SLC17A5 profile across patient tissues and cancer cell-line models. SLC17A5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC17A5 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SLC17A5 RNA expression shows 19,646 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where SLC17A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC17A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC17A5 survival associations across molecular data types. SLC17A5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC17A5 RNA expression–survival associations across cancer types. High SLC17A5 expression shows unfavorable associations in LIHC, UVM, CESC and ESCA, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC17A5 RNA expression.
This table summarizes SLC17A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC17A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC17A5 shows lower tumor expression in KICH, READ and COAD and higher tumor expression in LIHC, THCA and STAD. The KICH box plot shows higher SLC17A5 RNA expression in normal versus tumor tissue (log2 FC = −1.451, t-test p < 0.001).
This table shows molecular features associated with SLC17A5 in patient tissues and cancer cell lines. In patient samples, SLC17A5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC17A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
